IFN-γ gene expression increased only in anti-PD-1, anti-TIGIT:mIgG2a monotherapy and anti-PD-1 + anti-TIGIT:mIgG2a combination therapy (Figure 6G) groups as compared to isotype controls and corroborates the anti-tumor efficacy we observe in multiple models with those treatments. Here, PDCD1 is linked to neoplasm.